Donor-specific antibodies and liver transplantation

Human Immunology

Volumn 77, Issue 11, 2016, Pages 1063-1070

  Del Bello, Arnaud ^a,b   Congy Jolivet, Nicolas ^a,b   Danjoux, Marie ^c   Muscari, Fabrice ^b,d   Kamar, Nassim ^a,b,c  

^a CHU RANGUEIL   (France)

^b UNIVERSITÉ PAUL SABATIER   (France)

^c CHU PURPAN   (France)

^d CHU de Toulouse ^*  (France)

Author keywords

Antibody mediated rejection; Donor specific antibodies; Humoral response; Liver transplantation; Treatment

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANTIBODY; GLUTATHIONE TRANSFERASE; TRANSFERASE INHIBITOR; ALLOANTIBODY; HLA ANTIGEN;

ANTIBODY MEDIATED REJECTION; ANTIBODY SPECIFICITY; CHRONIC GRAFT REJECTION; CLINICAL FEATURE; DISEASE ASSOCIATION; DONOR; GRAFT SURVIVAL; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMORAL IMMUNITY; INCIDENCE; LIVER; LIVER FIBROSIS; LIVER TRANSPLANTATION; MAJOR HISTOCOMPATIBILITY COMPLEX; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TREATMENT PLANNING; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; GRAFT REJECTION; HISTOCOMPATIBILITY; IMMUNOLOGY; METABOLISM;

ANTIBODY-DEPENDENT CELL CYTOTOXICITY; GRAFT REJECTION; HLA ANTIGENS; HUMANS; IMMUNITY, HUMORAL; ISOANTIBODIES; LIVER TRANSPLANTATION; ORGAN SPECIFICITY; TRANSPLANTATION IMMUNOLOGY;

EID: 84959564624     PISSN: 01988859     EISSN: 18791166     Source Type: Journal    
DOI: 10.1016/j.humimm.2016.02.006     Document Type: Review

References (70)

1. [1] Ogura, K., Koyama, H., Takemoto, S., Terasaki, P.I., Busuttil, R.W., Significance of a positive crossmatch on outcome in human liver transplantation. Transplant. Proc., 24, 1992, 1465.
2. [2] Ogura, K., Terasaki, P.I., Koyama, H., Chia, J., Imagawa, D.K., Busuttil, R.W., High one-month liver graft failure rates in flow-cytometry crossmatch-positive recipients. Clin. Transplant. 8 (1994), 111–115.
3. [3] Takaya, S., Duquesnoy, R., Iwaki, Y., Demetris, J., Yagihashi, A., Bronsther, O., et al. Positive crossmatch in primary human liver allografts under cyclosporine or FK 506 therapy. Transplant. Proc. 23 (1991), 396–399.
4. [4] OPTN/SRTR 2012: Annual Data Report, 2012.
5. [5] Morath, C., Opelz, G., Zeier, M., Süsal, C., Clinical relevance of HLA antibody monitoring after kidney transplantation. J. Immunol. Res., 2014, 10.1155/2014/845040.
6. [6] Loupy, A., Lefaucheur, C., Vernerey, D., Prugger, C., Duong vanHuyen, J.P., Mooney, N., et al. Complement-binding anti-HLA antibodies and kidney-allograft survival. N. Engl. J. Med. 369 (2013), 1215–1226.
7. [7] Berry, G.J., Burke, M.M., Andersen, C., Bruneval, P., Fedrigo, M., Fishbein, M.C., et al. The 2013 International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J. Heart Lung Transplant. 32 (2013), 1147–1162.
8. [8] Witt, C.A., Gaut, J.P., Yusen, R.D., Byers, D.E., Iuppa, J.A., Bennett, B.K., et al. Acute antibody-mediated rejection after lung transplantation. J. Heart Lung Transplant. 32 (2013), 1034–1040.
9. [9] Redfield, R.R., Kaufman, D.B., Odorico, J.S., Diagnosis and treatment of pancreas rejection. Curr. Transplant. Rep. 2 (2015), 169–175.
10. [10] Tait, B.D., Süsal, C., Gebel, H.M., Nickerson, P.W., Zachary, A.A., Claas, F.H., et al. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 95 (2013), 19–47.
11. [11] Reinsmoen, N.L., Lai, C.H., Mirocha, J., Cao, K., Ong, G., Naim, M., et al. Increased negative impact of donor HLA-specific together with non-HLA-specific antibodies on graft outcome. Transplantation 97 (2014), 595–601.
12. [12] Alvarez-Márquez, A., Aguilera, I., Gentil, M.A., Caro, J.L., Bernal, G., Fernández Alonso, J., et al. Donor-specific antibodies against HLA, MICA, and GSTT1 in patients with allograft rejection and C4d deposition in renal biopsies. Transplantation 87 (2009), 94–99.
13. [13] Andres, G.A., Ansell, I.D., Halgrimson, C.G., Hsu, K.C., Porter, K.A., Starzl, T.E., et al. Immunopathological studies of orthotopic human liver allografts. Lancet 7745 (1972), 275–280.
14. [14] Nakamura, K., Murase, N., Becich, M.J., Furuya, T., Todo, S., Fung, J.J., et al. Liver allograft rejection in sensitized recipients. Observations in a clinically relevant small animal model. Am. J. Pathol. 142 (1993), 1383–1391.
15. [15] Davies, H.S., Pollard, S.G., Calne, R.Y., Soluble HLA antigens in the circulation of liver graft recipients. Transplantation 47 (1989), 524–527.
16. [16] Steinhoff, G., Wonigeit, K., Pichlmayr, R., Analysis of sequential changes in major histocompatibility complex expression in human liver grafts after transplantation. Semin. Liver Dis. 12 (1988), 51–59.
17. [17] Demetris, A.J., Murase, N., Nakamura, K., Iwaki, Y., Yagihashi, A., Valdivia, L., et al. Immunopathology of antibodies as effectors of orthotopic liver allograft rejection. Semin. Liver Dis. 12 (1992), 51–59.
18. [18] Li, W., Kuhr, C.S., Zheng, X.X., Carper, K., Thomson, A.W., Reyes, J.D., Perkins, J.D., New insights into mechanisms of spontaneous liver transplant tolerance: the role of Foxp3-expressing CD25+CD4+ regulatory T cells. Am. J. Transplant. 8 (2008), 1639–1651.
19. [19] Qian, S., Lu, L., Fu, F., Li, Y., Li, W., Starzl, T.E., et al. Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J. Immunol. 158 (1997), 4654–4661.
20. [20] Minguela, A., Martin, L., Torio, A., Muro, M., Garcia-Alonso, A.M., Moya-Quiles, M.R., et al. CD28-CTLA-4 and CD80/86 costimulatory molecules are mainly involved in acceptance or rejection of human liver transplant. Hum. Immunol. 61 (2000), 658–659.
21. ∗0302 allele frequency and acute rejection. Hum. Immunol. 56 (1997), 70–76.
22. [22] Knechtle, S.J., Kolbeck, P.C., Tsuchimoto, S., Coundouriotis, A., Sanfilippo, F., Bollinger, R.R., Humoral rejection of rat hepatic transplants by passive transfer of serum. Transplant. Proc. 19 (1987), 1072–1076.
23. [23] Steinhoff, G., Wonigeit, K., Pichlmayr, R., Analysis of sequential changes in mayor histocompatibility complex expression in human liver grafts after transplantation. Transplantation 45 (1988), 394–401.
24. [24] Takacs, L., Szende, B., Monostori, E., Rot, A., Lapis, K., Szecseny, A., et al. Expression of HLA-DR antigens on bileduct cells of rejected liver transplant. Lancet 1500 (1983), 8365–8366.
25. [25] Demetris, A.J., Lasky, S., Thiel, D.H.V., Starzl, T.E., Whiteside, T., Induction of HLA-DR/IA antigens in human liver allografts. Transplantation 40 (1985), 504–509.
26. [26] Gouw, A.S.H., Houthoff, H.J., Huitema, S., Beelen, J.M., Gips, C.H., Poppema, S., Expression of major histocompatibility complex antigens and replacement of donor cells by recipient ones in human liver grafts. Transplantation 43 (1987), 291–296.
27. [27] Miyagawa-Hayashino, A., Yoshizawa, A., Uchida, Y., Egawa, H., Yurugi, K., Masuda, S., et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transplant. 18 (2012), 1333–1342.
28. [28] Del Bello, A., Congy-Jolivet, N., Muscari, F., Lavayssiere, L., Esposito, L., Cardeau-Desangles, I., et al. Prevalence, incidence and risk factors for donor specific anti-HLA antibodies in maintenance liver transplant patients. Am. J. Transplant. 14 (2014), 867–875.
29. [29] Jiang, X., Morita, M., Sugioka, A., Harada, M., Kojo, S., Wakao, H., et al. The importance of CD25+ CD4+ regulatory T cells in mouse hepatic allograft tolerance. Liver Transplant. 12 (2006), 1112–1118.
30. [30] Demetris, A.J., Jaffe, R., Tzakis, A., Ramsey, G., Todo, S., Belle, S., et al. Antibody-mediated rejection of human orthotopic liver allografts: Transplantation across ABO Blood Group Barriers. Am. J. Pathol. 21 (1989), 2217–2220.
31. [31] Watson, R., Kozslowski, T., Nickeleit, V., Woosley, J.T., Schmitz, J.L., Zacks, S.L., et al. Isolated donor specific alloantibodies-mediated rejection after ABO compatible liver transplantation. Am. J. Transplant. 6 (2006), 3022–3029.
32. [32] O'Leary, J.G., Kaneku, H., Jennings, L.W., Bañuelos, N., Susskind, B.M., Terasaki, P.I., Klintmalm, G.B., Preformed class II donor-specific antibodies are associated with increased risk of early rejection after liver transplantation. Liver Transplant. 19 (2013), 973–980.
33. [33] Kozlowski, T., Rubinas, T., Nickeleit, V., Woosley, J., Schmitz, J., Collins, D., et al. Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodies. Liver Transplant. 17 (2011), 357–368.
34. [34] Kozlowski, T., Andreoni, K., Schmitz, J., Hayashi, P.H., Nickeleit, V., Sinusoidal C4d deposits in liver allograft indicate an antibody mediated response: diagnostic considerations in the evaluation of liver allografts. Liver Transplant. 6 (2012), 641–658.
35. [35] Del Bello, A., Congy-Jolivet, N., Danjoux, M., Muscari, F., Lavayssiere, L., Esposito, L., et al. De novo donor-specific antibodies mediated rejection in liver transplant patients. Transplant. Int. 28 (2015), 1371–1382.
36. [36] Starzl, T.E., Demetris, A.J., Todo, S., Kang, Y., Tzakis, A., Duquesnoy, R., et al. Evidence for hyperacute rejection of human liver grafts: the case of the canary kidneys. Clin. Transplant. 3 (1989), 37–45.
37. [37] Musat, A.I., Pigott, C.M., Ellis, T.M., Agni, R.M., Leverson, G.E., Powell, A.J., Richards, K.R., D'Alessandro, A.M., Lucey, M.R., Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantation. Liver Transplant. 19 (2013), 1132–1141.
38. [38] O'Leary, J.G., Kaneku, H., Demetris, A.J., Marr, J.D., Shiller, S.M., Susskind, B.M., et al. Antibody-mediated rejection as a contributor to previously unexplained early liver allograft loss. Liver Transplant. 20 (2014), 218–227.
39. [39] O'Leary, J.G., Kaneku, H., Banuelos, N., Jennings, L.W., Klintmalm, G.B., Terasaki, P.I., Impact of IgG3 subclass and C1q-fixing donor-specific HLA alloantibodies on rejection and survival in liver transplantation. Am. J. Transplant. 15 (2015), 1003–1013.
40. [40] Demetris, A.J., Jaffe, R., Tzakis, A., Ramsey, G., Todo, S., Belle, S., et al. Antibody-mediated rejection of human orthotopic liver allografts: A Study of Liver Transplantation across ABO Blood Group Barriers. Am. J. Pathol. 132 (1988), 489–502.
41. [41] O'Leary, J.G., Shiller, M.S., Bellamy, C., Nalesnik, M.A., Kaneku, H., Jennings, L.W., et al. Acute liver allograft antibody-mediated rejection: an inter-institutional study of significant histopathological features. Liver Transplant. 20 (2014), 1244–1255.
42. [42] Lunz, J., Ruppert, K.M., Cajaiba, M.M., Isse, K., Bentlejewski, C.A., Minervini, M., et al. Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring?. Am. J. Transplant. 12 (2012), 171–182.
43. [43] Hubscher, S.G., Antibody-mediated rejection in the liver allograft. Curr. Opin. Organ Transplant. 17 (2012), 280–286.
44. [44] Bellamy, C.O., Complement C4d immunochemistry in the assessment of liver allograft biopsy samples: applications and pitfalls. Liver Transplant. 17 (2011), 747–750.
45. [45] O'Leary, J.G., Demetris, A.J., Friedman, L.S., Gebel, H.M., Halloran, P.F., Kirk, A.D., et al. The role of donor-specific HLA alloantibodies in liver transplantation. Am. J. Transplant. 14 (2014), 779–787.
46. [46] Musat, A.I., Agni, R.M., Wai, P.Y., Pirsch, J.D., Lorentzen, D.F., Powell, A., et al. The significance of donor-specific HLA antibodies in rejection and ductopenia development in ABO compatible liver transplantation. Am. J. Transplant. 11 (2011), 500–510.
47. [47] Demetris, A.J., Nakamura, K., Yagihashi, A., Iwaki, Y., Takaya, S., Hartman, G.G., et al. A clinicopathological study of human liver allograft recipients harboring preformed IgG lymphocytotoxic antibodies. Hepatology 16 (1992), 671–681.
48. [48] Paterno, F., Shiller, M., Tillery, G., O'Leary, J.G., Susskind, B., Trotter, J., Klintmalm, G.B., Bortezomib for acute antibody-mediated rejection in liver transplantation. Am. J. Transplant. 12 (2012), 2526–2531.
49. [49] O'Leary, J.G., Kaneku, H., Susskind, B.M., Susskind, B.M., Jennings, L.W., Neri, M.A., et al. High mean fluorescence intensity donor specific anti-HLA antibodies associated with chronic rejection postliver transplant. Am. J. Transplant. 11 (2011), 1868–1876.
50. [50] Kaneku, H., O'Leary, J.G., Taniguchi, M., Susskind, B.M., Terasaki, P., Klintmalm, G.B., Donor-specific human leucocyte antigen antibodies of the immunoglobulin G3 subclass are associated with chronic rejection and graft loss after liver transplantation. Liver Transplant. 8 (2012), 984–992.
51. [51] Kamar, N., Lavayssière, L., Muscari, F., Selves, J., Guilbeau-Frugier, C., Cardeau, I., et al. Early plasmapheresis and rituximab for acute humoral rejection after ABO-compatible liver transplantation. World J. Gastroenterol. 15 (2009), 3426–3430.
52. [52] Wilson, C.H., Agarwal, K., Carter, V., Burt, A.D., Hübscher, S., Talbot, D., et al. Late humoral rejection in a compliant ABO-compatible liver transplant recipient. Transplantation 82 (2006), 988–989.
53. [53] O'Leary, J.G., Cai, J., Freeman, R., Banuelos, N., Hart, B., Johnson, M., et al. Proposed diagnostic criteria for chronic antibody-mediated rejection in liver allografts. Am. J. Transplant. 16 (2015), 603–614.
54. [54] Miyagawa-Hayashino, A., Yoshizawa, A., Uchida, Y., Egawa, H., Yurugi, K., Masuda, S., et al. Progressive graft fibrosis and donor-specific human leukocyte antigen antibodies in pediatric late liver allografts. Liver Transplant. 11 (2012), 1333–1342.
55. [55] O'Leary, J.G., Kaneku, H., Jennings, L., Susskind, B.M., Terasaki, P.I., Klintmalm, G.B., Donor-specific alloantibodies are associated with fibrosis progression after liver transplantation in hepatitis C virus-infected patients. Liver Transplant. 20 (2014), 655–663.
56. [56] Sharma, S., Gurukar, A., Jabbour, N., Biliary strictures following liver transplantation. Liver Transplant. 14 (2008), 759–769.
57. [57] Iacob, S., Cicinnati, V.R., Dechene, A., Lindemann, M., Heinemann, F.M., Rebmann, V., et al. Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation. Liver Int. 32 (2012), 1253–1261.
58. [58] Castillo-Rama, M., Castro, M.J., Bernardo, I., Meneu-Diaz, J.C., Elola-Olaso, A.M., Calleja-Antolin, S.M., et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transplant. 14 (2008), 554–562.
59. [59] Muro, M., Marin, L., Miras, M., Moya-Quiles, R., Minguela, A., Sanchez-Bueno, F., et al. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre. Transplant. Immunol. 14 (2005), 91–97.
60. [60] Fontana, M., Moradpour, D., Aubert, V., Pantaleo, G., Pascual, M., Prevalence of anti-HLA antibodies after liver transplantation. Transplant. Int. 23 (2010), 858–859.
61. [61] Taner, T., Gandhi, M.J., Sanderson, S.O., Poterucha, C.R., De Goey, S.R., Stegall, M.D., Heimbach, J.K., Prevalence, course and impact of HLA donor-specific antibodies in liver transplantation in the first year. Am. J. Transplant. 12 (2012), 1504–1510.
62. [62] Kaneku, H., O’ Leary, J.G., Banuelos, N., Jennings, L.W., Susskind, B.M., Klintmalm, G.B., et al. De novo donor-specific HLA antibodies decrease patients and graft survival in liver transplant recipients. Am. J. Transplant. 13 (2013), 1541–1548.
63. [63] Dragun, D., Muller, D.N., Brasen, J.H., Fritsche, L., Nieminen-Kelhä, M., Dechend, R., et al. Angiotensin II type 1 receptor activating antibodies in renal transplantation. N. Engl. J. Med. 352 (2005), 558–569.
64. [64] Yoshiji, H., Kuriyama, S., Noguchi, R., Ikenaka, Y., Kitade, M., Kaji, K., et al. Angiotensin-II and vascular endothelial growth factor interaction plays an important role in rat liver fibrosis development. Hepatol. Res. 36 (2006), 124–129.
65. [65] Kurikawa, N., Suga, M., Kuroda, S., Yamada, K., Ishikawa, H., An angiotensin II type 1 receptor antagonist, olmesartan medoxomil, improves experimental liver fibrosis by suppression of proliferation and collagen synthesis in activated hepatic stellate cells. Br. J. Pharmacol. 139 (2003), 1085–1094.
66. [66] Ohe, H., Uchida, Y., Yoshizawa, A., Hirao, H., Taniguchi, M., Maruya, E., et al. Association of anti-human leukocyte antigen and anti-angiotensin II type 1 receptor antibodies with liver allograft fibrosis after immunosuppression withdrawal. Transplantation 98 (2014), 1105–1111.
67. [67] Aguilera, I., Wichmann, I., Sousa, J.M., Bernardos, A., Franco, E., García-Lozano, J.R., et al. Antibodies against glutathione S-transferase T1 (GSTT1) in patients with de novo immune hepatitis following liver transplantation. Clin. Exp. Immunol. 126 (2001), 535–539.
68. [68] Molinero, L.L., Domaica, C.I., Fuertes, M.B., Girart, M.V., Rossi, L.E., Zwirner, N.W., Intracellular expression of MICA in activated CD4 T lymphocytes and protection from NK cell-mediated MICA-dependent cytotoxicity. Hum. Immunol. 67 (2006), 170–182.
69. [69] Zou, Y., Heinemann, F.M., Grosse-Wilde, H., Sireci, G., Wang, Z., Lavingia, B., et al. Detection of anti-MICA antibodies in patients awaiting kidney transplantation, during the post-transplant course, and in eluates from rejected kidney allografts by Luminex flow cytometry. Hum. Immunol. 67 (2006), 230–237.
70. [70] Zou, Y., Qin, Z., Silveus, A., Fan, Y., Stastny, P., Polymorphisms of MICA recognized by human alloantibodies. Immunogenetics 61 (2009), 91–100.